BRPI0412182A - composição para tratamento e/ou prevenção de disfunções associadas com diabetes melito do tipo 2 e resistência à insulina - Google Patents

composição para tratamento e/ou prevenção de disfunções associadas com diabetes melito do tipo 2 e resistência à insulina

Info

Publication number
BRPI0412182A
BRPI0412182A BRPI0412182-1A BRPI0412182A BRPI0412182A BR PI0412182 A BRPI0412182 A BR PI0412182A BR PI0412182 A BRPI0412182 A BR PI0412182A BR PI0412182 A BRPI0412182 A BR PI0412182A
Authority
BR
Brazil
Prior art keywords
composition
insulin resistance
treating
diabetes mellitus
dysfunction
Prior art date
Application number
BRPI0412182-1A
Other languages
English (en)
Inventor
Etienne Pouteau
Michel Krempf
Catherine Mace
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33547601&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0412182(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BRPI0412182A publication Critical patent/BRPI0412182A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

"COMPOSIçãO PARA TRATAMENTO E/OU PREVENçãO DE DISFUNçõES ASSOCIADAS COM DIABETES MELITO DO TIPO 2 E RESISTêNCIA à INSULINA". A presente invenção refere-se ao uso de uma composição para tratamento, prevenção e/ou melhora de disfunções metabólicas associadas com diabetes melito do Tipo 2 e resistência à insulina, a dita composição compreendendo fibras acetogênicas.
BRPI0412182-1A 2003-06-30 2004-06-30 composição para tratamento e/ou prevenção de disfunções associadas com diabetes melito do tipo 2 e resistência à insulina BRPI0412182A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03014816 2003-06-30
PCT/EP2004/007092 WO2005002612A1 (en) 2003-06-30 2004-06-30 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance

Publications (1)

Publication Number Publication Date
BRPI0412182A true BRPI0412182A (pt) 2006-08-22

Family

ID=33547601

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0412189-9A BRPI0412189A (pt) 2003-06-30 2004-06-30 composição para tratar e/ou prevenir disfunções associadas à diabetes melito do tipo 2
BRPI0412182-1A BRPI0412182A (pt) 2003-06-30 2004-06-30 composição para tratamento e/ou prevenção de disfunções associadas com diabetes melito do tipo 2 e resistência à insulina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0412189-9A BRPI0412189A (pt) 2003-06-30 2004-06-30 composição para tratar e/ou prevenir disfunções associadas à diabetes melito do tipo 2

Country Status (13)

Country Link
US (2) US20060148754A1 (pt)
EP (2) EP1648483B1 (pt)
JP (1) JP2009513505A (pt)
CN (2) CN1835762B (pt)
AT (1) ATE397453T1 (pt)
BR (2) BRPI0412189A (pt)
CA (2) CA2531058A1 (pt)
DE (1) DE602004014275D1 (pt)
ES (1) ES2307020T3 (pt)
IL (2) IL172898A0 (pt)
PT (1) PT1648483E (pt)
WO (4) WO2005002612A1 (pt)
ZA (2) ZA200600812B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2489942A1 (en) * 2002-07-01 2004-01-08 Unilever Plc Satiety inducing composition
JP2006510367A (ja) * 2002-12-20 2006-03-30 ユニリーバー・ナームローゼ・ベンノートシヤープ 血糖調節組成物
DE10331202A1 (de) 2003-07-10 2005-03-31 S.K. Enterprise Gmbh Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms
EP1774973A1 (en) * 2005-10-12 2007-04-18 Nutricia N.V. Leucine rich composition
DE102006036285A1 (de) 2006-08-03 2008-02-07 "S.U.K." Beteiligungs Gmbh Fraktionen aus Molkepermeat und deren Verwendung zur Prävention und Therapie des Typ-2 Diabetes und des Metabolischen Syndroms
US20080107787A1 (en) * 2006-11-02 2008-05-08 The Coca-Cola Company Anti-Diabetic Composition with High-Potency Sweetener
CA2676518A1 (en) * 2008-08-29 2010-02-28 Kraft Foods Global Brands Llc Whey protein pre-load
JP2010105946A (ja) * 2008-10-29 2010-05-13 Nof Corp 筋タンパク質増強剤及びこれを含む医薬品または食品
EP2583562A1 (en) * 2011-10-21 2013-04-24 Nestec S.A. Use of whey protein micelles for infants at risk of obesity or diabetes
EP2583564A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Use of whey protein micelles for improving insulin profile in diabetic patients
AU2013204801B2 (en) 2012-05-23 2014-11-06 Omniblend Innovation Pty Ltd Composition and method for management of diabetes or pre-diabetes
SG11201502205SA (en) * 2012-09-21 2015-04-29 Abbott Lab Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes
WO2014134225A2 (en) * 2013-02-26 2014-09-04 Pronutria, Inc. Nutritive polypeptides, formulations and methods for treating disease and improving muscle health and maintenance
JP2016000707A (ja) * 2014-06-12 2016-01-07 有限会社 坂本薬草園 インスリン抵抗性改善剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU698980A1 (ru) * 1977-11-03 1979-11-25 Ордена Ленина Институт Элементоорганических Соединений Ан Ссср Способ получени смеси аминокислот
US4496606A (en) * 1983-04-29 1985-01-29 Nabisco Brands, Inc. Guar gum food bar
US4921877A (en) * 1986-10-27 1990-05-01 Abbott Laboratories Liquid nutritional formula for glucose intolerance
JPH0327262A (ja) * 1989-06-22 1991-02-05 Sanpuku Seimen:Kk りんごファイバー入り麺類
CN1087495A (zh) * 1993-11-16 1994-06-08 朱建华 低热量保健饮料及其制作方法
CN1146305A (zh) * 1995-09-28 1997-04-02 石河子医学院 糖尿病营养粉
US5795606A (en) * 1995-10-02 1998-08-18 Hercules Incorporated Method for preparing a coated food
RU2087531C1 (ru) * 1996-05-28 1997-08-20 Владимир Константинович Латов Способ получения пищевого биологически-активного продукта переработки дрожжей
US20030113390A1 (en) * 1998-11-25 2003-06-19 Hoie Lars Henrik Composition comprising soy protein, dietary fibers and a phytoestrogen compound and use thereof in the prevention and/or treatment of various diseases
US6462029B1 (en) * 1999-02-23 2002-10-08 Econugenics Compositions and methods for treating mammals with modified alginates and modified pectins
GB9927603D0 (en) * 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
CA2398445C (en) * 2000-02-01 2012-04-03 Stevia Aps A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
US6207638B1 (en) * 2000-02-23 2001-03-27 Pacifichealth Laboratories, Inc. Nutritional intervention composition for enhancing and extending satiety
JP3633852B2 (ja) * 2000-06-06 2005-03-30 伶輝 程 三価クロム複合物、その乳製品およびその製造方法
US6365176B1 (en) * 2000-08-08 2002-04-02 Functional Foods, Inc. Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy
DE20017622U1 (de) * 2000-10-13 2001-04-12 Neuendorf, Ernst-Günter, 31737 Rinteln Mischpressling als Vollwert-Alleinfutter
DE10117185A1 (de) * 2001-03-02 2002-10-02 Trepel Friedrich Mittel zur Behandlung des Diabetes mellitus
CA2439793A1 (en) * 2001-03-02 2002-09-12 Lichtwer Pharma Ag Composition for the treatment of diabetes mellitus
ATE451928T1 (de) * 2001-08-31 2010-01-15 Univ Rutgers Verfahren zur behandlung von krankheiten mit pflanzenextrakten
US6875459B2 (en) * 2001-09-10 2005-04-05 Henry B. Kopf Method and apparatus for separation of milk, colostrum, and whey
US6706305B2 (en) * 2001-10-31 2004-03-16 Conagra Foods Inc. Low glycemic index bread
EP1332759B1 (en) * 2002-02-04 2005-09-28 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical and nutritional compositions containing a di- or oligosaccharide as insulin secretion promoter

Also Published As

Publication number Publication date
PT1648483E (pt) 2008-06-23
WO2005002612A8 (en) 2006-04-06
CA2531081A1 (en) 2005-01-13
ZA200600818B (en) 2007-04-25
CN1835762B (zh) 2010-05-12
US20060159770A1 (en) 2006-07-20
WO2005002600A2 (en) 2005-01-13
WO2005002602A3 (en) 2005-04-14
CN1835762A (zh) 2006-09-20
IL172916A0 (en) 2006-06-11
CN1835760A (zh) 2006-09-20
JP2009513505A (ja) 2009-04-02
DE602004014275D1 (de) 2008-07-17
WO2005000325A2 (en) 2005-01-06
ATE397453T1 (de) 2008-06-15
EP1653980A2 (en) 2006-05-10
WO2005000325A3 (en) 2005-04-14
EP1648483A1 (en) 2006-04-26
IL172898A0 (en) 2006-06-11
ZA200600812B (en) 2007-04-25
WO2005002612A1 (en) 2005-01-13
WO2005002600A3 (en) 2005-03-31
ES2307020T3 (es) 2008-11-16
BRPI0412189A (pt) 2006-08-22
EP1648483B1 (en) 2008-06-04
US20060148754A1 (en) 2006-07-06
CA2531058A1 (en) 2005-01-06
WO2005002602A2 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
BRPI0412182A (pt) composição para tratamento e/ou prevenção de disfunções associadas com diabetes melito do tipo 2 e resistência à insulina
BRPI0511703B8 (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição
BRPI0411484A (pt) composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica
BR0309855A (pt) Pirazolpiridinas substituìdas com carbamato
BRPI0508098A (pt) compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
EA200501000A2 (ru) Связывающие агенты, ингибирующие миостатин
AU6842701A (en) Antibodies that immunospecifically bind to blys
CL2008000915A1 (es) Compuestos triciclicos moduladores de 11beta-hidroxiesteroidedeshidrogenasa tipo 1; y uso en el tratamiento, prevencion y/o profilaxis de enfermedades tales como sindrome metabolico, resistencia a la insulina, dislipidemia, hipertension y obesidad.
CL2007002841A1 (es) Compuestos derivados de indol, antagonistas del receptor de glucagion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes mellitus tipo 2, hiperglucemia, diabetes o resistencia a la insulina.
IL202106A0 (en) Gaboxadol for treating depression and other affective disorders
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
MY182720A (en) Pharmaceutical compositions
PT1173197E (pt) Intervencao metabolica com glp-1, para melhorar a funcao do tecido isquemico e reperfundido
BRPI0519593A2 (pt) composto, mÉtodos de tratar distérbios neurodegenerativos e complicaÇÕes devido a derrame ou trauma na cabeÇa, e de preparar um composto, e, uso de um composto
BRPI0507189A (pt) uso combinado de um agonista de glp-1 e compostos de gastrina
MY152037A (en) Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
MX2009006709A (es) Tratamiento de enfermedades relacionadas con il-1beta.
EP2003127A4 (en) MIXTURE OF CYCLIC PHENOLSULFIDE AND MEANS FOR CHECKING THE LOAD OR TONER, AND THE THAT USES THIS MIXTURE
WO2007133731A3 (en) Creatine-ligand compounds and methods of use thereof
WO2003055979A3 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
WO2006065842A3 (en) 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof
CL2004000391A1 (es) Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.
ATE504595T1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz
BRPI0721333A8 (pt) Composição útil para o tratamento de diabetes tipo 2

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 35/78 , A61P 3/10 , A61P 3/06 , A23L 1/0524 , A23L 1/0526 , A23L 1/053

Ipc: A23L 1/308 (2006.01), A61P 3/10 (2006.01), A61P 3/

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2261 DE 06/05/2014.

B15K Others concerning applications: alteration of classification

Ipc: A61K 35/20 (2006.01), A61K 38/16 (2006.01), A61K 3